RenovoRx (Nasdaq:RNXT) announced that it priced an underwritten public offering of common stock worth proceeds of $12.1 million. Mountain View, California-based RenovoRx priced more than 11.5 million shares of common stock at $1.05 per share. It expects the proceeds to total approximately $12.1 million before deducting underwriting discounts, commissions and offering expenses. The company plans […]
Oncology
Boston Scientific to acquire hepatic artery infusion pump maker Intera Oncology
Boston Scientific (NYSE:BSX) announced today that it agreed to acquire infusion pump maker Intera Oncology for an undisclosed amount. Intera Oncology develops the Intera 3000 hepatic artery infusion pump and floxuridine, a chemotherapy drug. Both hold FDA approval. The pump administers hepatic artery infusion (HAI) therapy to treat tumors in the liver primarily caused by […]
RenovoRx to increase production of RenovoCath catheter delivery system
RenovoRx announced today that it plans to increase the production of its RenovoCath catheter-based delivery system. The Los Altos, California-based company cited increased demand for the delivery of diagnostic and/or therapeutic agents. It signed a new project work order with its principal manufacturing partner, Medical Murray, providing for an expanded relationship. The company looks to […]
Sirtex Medical begins European launch for microsphere delivery system following EU approval
Sirtex Medical announced today that it received EU MDR certification to market its SIR-Spheres Y-90 resin microspheres and delivery systems. EU MDR authorization enables Woburn, Massachusetts-based Sirtex to kick off a European launch for its Siros delivery system. Siros offers an intuitive, visual and adaptable solution for physicians to administer SIR-Spheres to liver cancer patients. […]
ICU Medical closes Minnesota facility, cuts 83 jobs
ICU Medical (Nasdaq: ICUI) filed with the state of Minnesota to confirm the termination of 83 employees following a facility closure. Minnesota’s State Rapid Response Team received a Worker Adjustment and Retraining Notification (WARN) letter from the maker of technologies for infusion therapy, oncology and critical care dated today, July 16. The letter outlined plans to […]
Carthera wins U.S., EU orphan drug designation for SonoCloud
Carthera announced today that it received FDA and European orphan drug designation (ODD) for the use of carboplatin with its SonoCloud. The designation allows Paris, France-based Carthera to use carboplatin chemotherapy in the treatment of malignant glioma. Carthera conducts this treatment through the use of SonoCloud, a device that emits ultrasound to temporarily increase the […]
RenovoRx raises $11.1M to support oncology drug delivery trial
RenovoRx (Nasdaq:RNXT) announced today that it closed a private placement worth gross proceeds of approximately $11.1 million. The $11.1 million adds to a separate private placement that brought in proceeds of approximately $6.1 million in January. RenovoRx plans to use the funds to strengthen its balance sheet and extend its cash runway into 2026. Funds […]
Carthera enrolls first patient in ultrasound drug delivery trial
Carthera announced today that it enrolled the first patient in the SONOBIRD pivotal trial for its SonoCloud device. Paris, France-based Carthera designed SonoCloud to treat a wide range of brain disorders. The device emits ultrasound to temporarily increase the permeability of blood vessels in the brain, improving therapeutic molecule delivery. After implantation in the skull, […]
RenovoRx closes $6.1M private placement
RenovoRx announced today that it closed a private placement bringing in gross proceeds of approximately $6.1 million. Los Altos, California-based RenovoRx develops precision oncology therapies based on a local drug delivery platform. Closing this funding round extends the company’s cash runway as it conducts its pivotal TIGer-PaC Phase III clinical trial. It expects the funds […]
UroGen to raise $120M to support sustained release hydrogel delivery platform
UroGen Pharma (Nasdaq:URGN) announced that it entered into a securities purchase agreement worth approximately $120 million. The placement includes the issuance of nearly 12.6 million ordinary shares or pre-funded warrants priced at $9.54 per share. UroGen expects the placement to close on or about today, subject to customary closing conditions. RA Capital Management and Great […]